Trinity Biotech
TRIB
67 hedge funds and large institutions have $93.7M invested in Trinity Biotech in 2017 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 18 increasing their positions, 19 reducing their positions, and 14 closing their positions.
0.01% less ownership
Funds ownership: 3.32% → 3.32% (-0.01%)
5% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 19
6% less funds holding
Funds holding: 71 → 67 (-4)
14% less capital invested
Capital invested by funds: $109M → $93.7M (-$15.2M)
29% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 14
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $201K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FWSM
First Wilshire Securities Management
Pasadena,
California
|
+$1.2M |
| 2 |
2L
22NW LP
Seattle,
Washington
|
+$960K |
| 3 |
LAM
Lapides Asset Management
Greenwich,
Connecticut
|
+$721K |
| 4 |
TA
Teton Advisors
Rye,
New York
|
+$569K |
| 5 |
FM
Fondren Management
Houston,
Texas
|
+$563K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$1.22M |
| 2 |
Boston Partners
Boston,
Massachusetts
|
-$1.21M |
| 3 |
BLA
Balter Liquid Alternatives
Boston,
Massachusetts
|
-$753K |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$705K |
| 5 |
GCM
Goldman Capital Management
New York
|
-$613K |
TRIB Hedge Fund Activity: Q1 2017 in Review
67 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Trinity Biotech (TRIB) for Q1 2017, worth a combined $93.7M — down 14% from $109M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of TRIB and 10 opened new positions — a net loss of 4 holders — while 19 trimmed existing stakes and 18 added.
The largest buyer was First Wilshire Securities Management, adding an estimated $1.2M. The largest seller was Millennium Management, cutting an estimated $1.22M.
- 67 institutional investors held Trinity Biotech (TRIB) as of Q1 2017, down from 71 in Q4 2016.
- Funds reported $93.7M of Trinity Biotech stock for Q1 2017, down 14% quarter-over-quarter.
- 10 funds opened new Trinity Biotech positions in Q1 2017 and 14 closed out, a net change of -4 holders.
- The largest Trinity Biotech buyer in Q1 2017 was First Wilshire Securities Management, an estimated $1.2M added.
- The largest Trinity Biotech seller in Q1 2017 was Millennium Management, an estimated $1.22M sold.
Based on aggregated 13F filings for Q1 2017.